Clairity shared a post on LinkedIn:
“Today in Boston, the first patient has received a Clairity Breast cancer risk score at Beth Israel Deaconess Medical Center in Chestnut Hill.
This moment marks the beginning of a new era in women’s health – one in which we shift from detecting breast cancer once it appears to predicting risk years earlier. Clairity Breast is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developing breast cancer using only her existing screening mammogram.
For far too long, many women have learned they’re at elevated risk only after diagnosis, often without a family history of the disease or known genetic mutation. By identifying risk earlier, clinicians can personalize screening and prevention strategies for women who might otherwise be considered “average risk.”
We’re proud to partner with Beth Israel Deaconess Medical Center and deeply grateful to the clinicians, patients and partners who made this milestone possible.
Read more here.”
Other articles featuring Clairity.